
    
      ANRS 173 ALTAR is a multicenter, comparative, international, open label, phase III randomized
      trial aiming at evaluating the non-inferiority of a TRI-BI (tritherapy-bitherapy) strategy
      (includes a 16 week - induction phase with 2 NRTI and a once daily integrase inhibitor
      followed by a bitherapy with TDF or TAF / XTC*) in its capacity to achieve viral suppression
      at week 48 versus immediate BI (bitherapy) strategy (DTG/3TC) in participants na√Øve to
      antiretroviral therapy with plasma HIV RNA strictly less than 50 000 copies/mL and CD4 cells
      count above 300/mm3.
    
  